Armata appoints Dr. Daniel Gilmer to Board; option award for 51,280 shares

Armata Pharmaceuticals, Inc.

Dr. Daniel Gilmer (39) appointed to Board effective April 24, 2026.
He will receive an option award to purchase 51,280 shares vesting over three years.
Non-management directors receive a cash retainer of $40,000 per year.
Gilmer is Senior Director at Pfizer and led the U.S. launch of PAXLOVID.
He is co-inventor of Streptococcus phage lysin exebacase (CF-301).

item 5.02item 7.01item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Dr. Daniel Gilmer

member of the Board

ARMP · Armata Pharmaceuticals, Inc.

Effective: 2026-04-24
Filed: Apr 27, 2026 23:59 UTC

On April 27, 2026, Armata Pharmaceuticals, Inc. (the “Company”) announced that the Board of Directors (the “Board”) appointed Dr. Daniel Gilmer, 39, as a member of the Board, effective as of April 24, 2026, to serve until the Company’s next annual meeting of the Company’s shareholders.

Source: SEC EDGAR

accession 0001104659-26-048997

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.